Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed in MTAP-deficient metastatic urothelial carcinoma
NCT02693717Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in urothelial carcinoma (UC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate up to 5 years. Started May 2017; status: terminated.
02
Drugs
pemetrexed
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02693717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02693717.